

CPC COOPERATIVE PATENT CLASSIFICATION

A HUMAN NECESSITIES

HEALTH; AMUSEMENT

A61 MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

NOTES

1. This subclass covers therapeutic activity of chemical compounds or medicinal preparations already classified as such in subclasses [A61K](#) or [C12N](#), or in classes [C01](#), [C07](#) or [C08](#)
2. In this subclass, the term "drugs" includes chemical compounds or compositions with therapeutic activity.
3. In this subclass, therapeutic activity is classified in all appropriate places {to the extent of all the different therapeutic activities stated in the claims and also significantly disclosed as examples in the disclosure}.
4. Attention is drawn to cases where the subject of the invention concerns only specific therapeutic activity of chemical compounds or medical preparations, and the chemical structure, compound, mixture or composition of this subject of the invention is known. In such cases, classification is made in both subclass [A61K](#) and subclass [A61P](#) as invention information. In addition, if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is considered to represent information of interest for search, it may also be classified as additional information. {There is no classification in [C01](#), [C07](#), [C08](#), [C12N](#) as additional information in CPC if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is known and classification is made in both subclass [A61K](#) and subclass [A61P](#) as invention information.}
5. The classification symbols of this subclass are not listed first when assigned to patent documents.

| | | | |
|-------------|--|------|---|
| 1/00 | Drugs for disorders of the alimentary tract or the digestive system | 5/02 | • of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin |
| 1/02 | • Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis | 5/04 | • • for decreasing, blocking or antagonising the activity of the hypothalamic hormones |
| 1/04 | • for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants | 5/06 | • of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH |
| 1/06 | • Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia | 5/08 | • • for decreasing, blocking or antagonising the activity of the anterior pituitary hormones |
| 1/08 | • for nausea, cinetosis or vertigo; Antiemetics | 5/10 | • of the posterior pituitary hormones, e.g. oxytocin, ADH |
| 1/10 | • Laxatives | 5/12 | • • for decreasing, blocking or antagonising the activity of the posterior pituitary hormones |
| 1/12 | • Antidiarrhoeals | 5/14 | • of the thyroid hormones, e.g. T3, T4 |
| 1/14 | • Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antifatulents | 5/16 | • • for decreasing, blocking or antagonising the activity of the thyroid hormones |
| 1/16 | • for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics | 5/18 | • of the parathyroid hormones |
| 1/18 | • for pancreatic disorders, e.g. pancreatic enzymes | 5/20 | • • for decreasing, blocking or antagonising the activity of PTH |
| 3/00 | Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) | 5/22 | • • for decreasing, blocking or antagonising the activity of calcitonin |
| 3/02 | • Nutrients, e.g. vitamins, minerals | 5/24 | • of the sex hormones |
| 3/04 | • Anorexiant; Antiobesity agents | 5/26 | • • Androgens |
| 3/06 | • Antihyperlipidemics | 5/28 | • • Antiandrogens |
| 3/08 | • for glucose homeostasis (pancreatic hormones A61P 5/48) | 5/30 | • • Oestrogens |
| 3/10 | • • for hyperglycaemia, e.g. antidiabetics | 5/32 | • • Antioestrogens |
| 3/12 | • for electrolyte homeostasis | 5/34 | • • Gestagens |
| 3/14 | • • for calcium homeostasis (vitamin D A61P 3/02; parathyroid hormones A61P 5/18; calcitonin A61P 5/22; osteoporosis A61P 19/10; bone metastasis A61P 35/04) | 5/36 | • • Antigestagens |
| | | 5/38 | • of the suprarenal hormones |
| | | 5/40 | • • Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids |
| 5/00 | Drugs for disorders of the endocrine system | 5/42 | • • for decreasing, blocking or antagonising the activity of mineralocorticosteroids |

| | | | |
|--------------|---|--------------|---|
| 5/44 | . . Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids | 15/14 | . for lactation disorders, e.g. galactorrhoea |
| 5/46 | . . for decreasing, blocking or antagonising the activity of glucocorticosteroids | 15/16 | . Masculine contraceptives |
| 5/48 | . of the pancreatic hormones | 15/18 | . Feminine contraceptives |
| 5/50 | . . for increasing or potentiating the activity of insulin | | |
| 7/00 | Drugs for disorders of the blood or the extracellular fluid | 17/00 | Drugs for dermatological disorders |
| 7/02 | . Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors | 17/02 | . for treating wounds, ulcers, burns, scars, keloids, or the like |
| 7/04 | . Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents | 17/04 | . Antipruritics |
| 7/06 | . Antianaemics | 17/06 | . Antipsoriatics |
| 7/08 | . Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04) | 17/08 | . Antiseborrheics |
| 7/10 | . Antioedematous agents; Diuretics | 17/10 | . Anti-acne agents |
| 7/12 | . Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10) | 17/12 | . Keratolytics, e.g. wart or anti-corn preparations |
| | | 17/14 | . for baldness or alopecia |
| 9/00 | Drugs for disorders of the cardiovascular system | 17/16 | . Emollients or protectives, e.g. against radiation |
| 9/02 | . Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives | 17/18 | . Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00) |
| 9/04 | . Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure | 19/00 | Drugs for skeletal disorders |
| 9/06 | . Antiarrhythmics | 19/02 | . for joint disorders, e.g. arthritis, arthrosis |
| 9/08 | . Vasodilators for multiple indications | 19/04 | . for non-specific disorders of the connective tissue |
| 9/10 | . for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis | 19/06 | . Antigout agents, e.g. antihyperuricemic or uricosuric agents |
| 9/12 | . Antihypertensives | 19/08 | . for bone diseases, e.g. rachitism, Paget's disease |
| 9/14 | . Vasoprotectives; Antihemorrhoidals; Drugs for varicose therapy; Capillary stabilisers | 19/10 | . . for osteoporosis |
| 11/00 | Drugs for disorders of the respiratory system | 21/00 | Drugs for disorders of the muscular or neuromuscular system |
| 11/02 | . Nasal agents, e.g. decongestants | 21/02 | . Muscle relaxants, e.g. for tetanus or cramps |
| 11/04 | . for throat disorders | 21/04 | . for myasthenia gravis |
| 11/06 | . Antiasthmatics | 21/06 | . Anabolic agents (androgens A61P 5/26) |
| 11/08 | . Bronchodilators | | |
| 11/10 | . Expectorants | 23/00 | Anaesthetics |
| 11/12 | . Mucolytics | 23/02 | . Local anaesthetics |
| 11/14 | . Antitussive agents | | |
| 11/16 | . Central respiratory analeptics | 25/00 | Drugs for disorders of the nervous system |
| 13/00 | Drugs for disorders of the urinary system | 25/02 | . for peripheral neuropathies |
| 13/02 | . of urine or of the urinary tract, e.g. urine acidifiers | 25/04 | . Centrally acting analgesics, e.g. opioids |
| 13/04 | . for urolithiasis | 25/06 | . Antimigraine agents |
| 13/06 | . Anti-spasmodics | 25/08 | . Antiepileptics; Anticonvulsants |
| 13/08 | . of the prostate | 25/10 | . . for petit-mal |
| 13/10 | . of the bladder | 25/12 | . . for grand-mal |
| 13/12 | . of the kidneys | 25/14 | . for treating abnormal movements, e.g. chorea, dyskinesia |
| 15/00 | Drugs for genital or sexual disorders (for disorders of sex hormones A61P 5/24); Contraceptives | 25/16 | . . Anti-Parkinson drugs |
| 15/02 | . for disorders of the vagina | 25/18 | . Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia |
| 15/04 | . for inducing labour or abortion; Uterotonics | 25/20 | . Hypnotics; Sedatives |
| 15/06 | . Abortifacient agents; Labour repressants | 25/22 | . Anxiolytics |
| 15/08 | . for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis | 25/24 | . Antidepressants |
| 15/10 | . for impotence | 25/26 | . Psychostimulants, e.g. nicotine, cocaine |
| 15/12 | . for climacteric disorders | 25/28 | . for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia |
| | | 25/30 | . for treating abuse or dependence |
| | | 25/32 | . . Alcohol-abuse |
| | | 25/34 | . . Tobacco-abuse |
| | | 25/36 | . . Opioid-abuse |
| | | 27/00 | Drugs for disorders of the senses |
| | | 27/02 | . Ophthalmic agents |
| | | 27/04 | . . Artificial tears; Irrigation solutions |
| | | 27/06 | . . Antiglaucoma agents or miotics |
| | | 27/08 | . . Mydriatics or cycloplegics |
| | | 27/10 | . . for accommodation disorders, e.g. myopia |

- 27/12 . . for cataracts
- 27/14 . . Decongestants or antiallergics
- 27/16 . Otologicals
- 29/00 Non-central analgesic, antipyretic or anti-inflammatory agents, e.g. antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)**
- 29/02 . without antiinflammatory effect
- 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics**
- 31/02 . Local antiseptics
- 31/04 . Antibacterial agents
- 31/06 . . for tuberculosis
- 31/08 . . for leprosy
- 31/10 . Antimycotics
- 31/12 . Antivirals
- 31/14 . . for RNA viruses
- 31/16 . . . for influenza or rhinoviruses
- 31/18 . . . for HIV
- 31/20 . . for DNA viruses
- 31/22 . . . for herpes viruses
- 33/00 Antiparasitic agents**
- 33/02 . Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- 33/04 . . Amoebicides
- 33/06 . . Antimalarials
- 33/08 . . for Pneumocystis carinii
- 33/10 . Anthelmintics
- 33/12 . . Schistosomicides
- 33/14 . Ectoparasiticides, e.g. scabicides
- 35/00 Antineoplastic agents**
- 35/02 . specific for leukemia
- 35/04 . specific for metastasis
- 37/00 Drugs for immunological or allergic disorders**
- 37/02 . Immunomodulators
- 37/04 . . Immunostimulants
- 37/06 . . Immunosuppressants, e.g. drugs for graft rejection
- 37/08 . Antiallergic agents ([antiasthmatic agents A61P 11/06](#); [ophthalmic antiallergics A61P 27/14](#))
- 39/00 General protective or antinotoxic agents**
- 39/02 . Antidotes
- 39/04 . Chelating agents
- 39/06 . Free radical scavengers or antioxidants
- 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution**
- 43/00 Drugs for specific purposes, not provided for in groups [A61P 1/00-A61P 41/00](#)**

NOTE

Classification is only made in this group when a specific therapeutic activity for a chemical compound or medicinal preparation has been clearly disclosed, the specific therapeutic activity not being appropriate to any of groups [A61P 1/00](#) - [A61P 41/00](#).